BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 14679126)

  • 1. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
    Alexopoulos A; Tryfonopoulos D; Karamouzis MV; Gerasimidis G; Karydas I; Kandilis K; Stavrakakis J; Stavrinides H; Georganta C; Ardavanis A; Rigatos G
    Ann Oncol; 2004 Jan; 15(1):95-9. PubMed ID: 14679126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives.
    Alexopoulos A; Karamouzis MV; Rigatos G
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):25-30. PubMed ID: 15199529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
    Levy C; Fumoleau P
    Cancer Treat Rev; 2005; 31 Suppl 4():S17-22. PubMed ID: 16360543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
    Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
    Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Kouroussis Ch; Papakotoulas P; Kalbakis K; Tryfonidis K; Vardakis N; Poppis E; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 May; 69(5):1345-52. PubMed ID: 22349809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
    Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
    Ryan DP; Lynch TJ; Grossbard ML; Seiden MV; Fuchs CS; Grenon N; Baccala P; Berg D; Finkelstein D; Mayer RJ; Clark JW
    Cancer; 2000 Jan; 88(1):180-5. PubMed ID: 10618622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
    Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
    Mavroudis D; Malamos N; Polyzos A; Kouroussis Ch; Christophilakis Ch; Varthalitis I; Androulakis N; Kalbakis K; Milaki G; Georgoulias V;
    Oncology; 2004; 67(3-4):250-6. PubMed ID: 15557786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study.
    Riccardi A; Brugnatelli S; Danova M; Giordano M; Pugliese P; Luchena G; Grasso D; Trotti G; Bertè R; Pansini G; Tinelli C
    Tumori; 2006; 92(1):6-12. PubMed ID: 16683377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
    Lopez M
    Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
    Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
    Pelegrí A; Calvo L; Mayordomo JI; Florián J; Vázquez S; Arcusa A; Martn-Richard M; Bayo JL; Virizuela J; Carrasco E; Antón A;
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):20-4. PubMed ID: 15199528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.